Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.4/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark the tool read-only/idempotent, and the description adds substantial behavior beyond that: it cascades across multiple lookup services, degrades gracefully when GLEIF/OpenFIGI are unavailable, returns figi_candidates instead of asserting on ambiguity, reports unresolved identifiers explicitly, and covers non-US/non-equity entities. None of this contradicts the annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness2/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The text is a dense wall of run-on parentheticals rather than a scannable description; the SUPPORTED TYPES section could be bulleted and the trigger examples shortened. Valuable details are buried in one enormous sentence, which reduces the description's usability for quick tool selection and parameter decision.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite the lack of an output schema, the description tells the agent what will be returned (identifiers with source labels, unresolved list, figi_candidates), how failures degrade, and what input forms are accepted. For a two-parameter tool with this complexity, the coverage is thorough and would let an agent invoke it correctly in edge cases.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description still adds meaning: it explains what each entity type resolves to (EDGAR spine, LEI ownership, FIGI, RxNorm citation), expands allowed inputs (ticker, CIK, ISIN, name), and warns about passing issuer-only names for bonds. This goes beyond the schema's short enum/value descriptions, though it also duplicates much of the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete natural-language triggers and states a clear verb+object: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input.' It names supported entity types and output identifiers (CIK, ticker, LEI, FIGI, RxCUI), and this is distinct from sibling tools like entity_profile or compare_entities because it is explicitly about ID lookup/resolution.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It provides explicit when-to-use guidance: 'Use FIRST whenever you have a name but need an ID' and supplies trigger phrasings. It does not, however, name alternatives or state when not to use it (e.g., when profile details rather than identifiers are needed), so it stops short of a full 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.3/5.0
Disambiguation3/5

There is notable overlap among the ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) and among the prediction market tools (bet_research, polymarket_arbitrage, polymarket_edges, polymarket_fill_risk, polymarket_kalshi_spread). While descriptions differentiate them, agents may struggle to choose the appropriate one without careful reading.

Naming Consistency3/5

Most tools follow a snake_case verb_noun pattern (e.g., ask_pipeworx, compare_entities), but the Repology-specific tools break this pattern with simple nouns like maintainer, problems, project, and repositories. This inconsistency makes the overall naming feel mixed.

Tool Count2/5

With 36 tools, the set is too large for a server focused on Repology package queries. Many tools are from the Pipeworx platform and include redundant variants (e.g., ask_pipeworx_beta, polymarket_edge_tracker), inflating the count without adding substantial new functionality.

Completeness2/5

For a server named Repology, the tool surface is severely incomplete: it lacks fundamental Repology operations like detailed package comparisons, version history exploration, and repository-specific queries. Even as a general data platform, there are gaps such as no batch export or aggregate statistics.